Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 3 22Phase NA 15Phase 1/2 7Phase 4 3Phase 2/3 3Phase 1 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 2Gynecologic 2Gastrointestinal 2Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 6Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lung Neoplasms 5Leukemia 5Glioblastoma 5Colorectal Neoplasms 5Stomach Neoplasms 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Head and Neck Neoplasms 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Ovarian Epithelial 4Brain Neoplasms 4Recurrence 3Gliosarcoma 3Esophageal Neoplasms 3Breast Neoplasms 3Astrocytoma 3Advanced Solid Tumors 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mesothelioma, Malignant 2

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Drug Therapy × Clear all
NCT05143970 2026-03-20

CHANCES

Institut Paoli-Calmettes

Phase 1 Recruiting
27 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT00004038 2013-02-07

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡